The rapid expansion of cannabis use for serious medical conditions across 33 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands and Guam reflects the mounting recognition of the drug’s therapeutic potential for a number of disorders and diseases. Although some of cannabis’ medicinal properties are well documented, rigorous research is needed to identify which patients will benefit from the drug, the most effective method of treatment, benefits versus risks and barriers to use.
Pennsylvania is first in the nation to require that research accompany legalization of cannabis for serious medical conditions, thereby positioning the Commonwealth as the leader in generating new knowledge that further defines the drug’s therapeutic applications.
Pennsylvania's authorizing legislation required that research accompany the legalization of cannabis for medical conditions, thereby positioning the Commonwealth as the leader in generating new knowledge regarding the therapeutic applications of cannabis.
PCOM, in collaboration with its Clinical Registrant partner Organic Remedies, has developed a multi-study research program that will contribute data and insights into medicinal cannabis’ use across populations, its impact on behavioral health and quality of life, and the drug’s therapeutic potential for the treatment of chronic pain and opioid management.
